Kirin Pharma Exec Tamao Watanabe On U.S. Biotech-Japan Pharma Collaborations: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Painstaking communication efforts, including putting plans in writing to overcome a language gap, are keys to Kirin’s partnership with Argos.
You may also be interested in...
Argos Therapeutics CEO Jeffrey Abbey on U.S. Biotech-Japan Pharma Collaborations: An Interview With PharmAsia News (Part 1 Of 2)
North Carolina-based Argos Therapeutics CEO Jeffrey Abbey recently spoke with PharmAsia News about the unique opportunities and challenges for U.S. biotechs looking to collaborate with Japanese pharma companies. Abbey discussed his experience partnering with Kirin Pharma and why it is a good time for U.S. biotechs to look for Japanese partners.
Kirin Holdings and Kyowa Hakko will seek to bring together each company's strength in biotech to create a global research and development-centered Japanese drug company. The two Tokyo-based companies announced a merger agreement Oct. 22, reflecting the ongoing consolidation of the Japanese drug industry
The Japanese government has decided to revise its drug pricing policies starting in April 2014. Changes include extending a price premium program for two more years, bundling the pricing of similar generic drugs, and reduced pricing on long-listed drugs.